Is this you?
Request access for M3 Wake Research with your @wakeresearch.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
M3 Wake Research
Unclaimed profileSMO · Research Triangle Park, NC · ~21 sites
Intera lens
ICP 7Lift (cardio sample) 0.09Recruit soph 0.57
Quality Scorecard (1–100)
Overall66Recruit80Ops63Sponsor59Ther57
Performance (observed)
Historical trials
129
Completed
78
Terminated/Withdrawn
15
Completion rate
84%
Active now
36
Phase 2
45
Phase 3
73
Realized enrollment
464,823
First study year
2016
Years active
10
Match confidence
low
Enrollment velocity (inf)
46,482
Therapeutic
Areas
Gastroenterology, Neuroscience, Dermatology, Endocrinology, Immunology, Women's Health, Internal Medicine, Vaccines, Infectious Diseases
Specialties
Multi-specialty (oncology, vaccines, primary care, women's health, gastroenterology)
Breadth (conditions)
142
Languages
English + Spanish (detected)
States
AL, AZ, CA, GA, NC, TN, TX
Recruitment (web observed)
Trial Finder
Yes
Patient database
Y
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Y - strong recruitment presence
Capability notes
Dedicated recruitment team; 950K+ subject database; high enrollment success across phases
Relationships
Sponsors
Pfizer; ModernaTX, Inc.; AbbVie; BioNTech SE; Bavarian Nordic; Seqirus
CROs
IQVIA Pty Ltd; Microbiome Health Sciences; Parexel; Syneos Health; Teva Branded Pharmaceutical Products R&D LLC
Partnerships
Acquired MSRA 2022
Owner / parent
Owned by M3 (Japanese company acquired Wake Research 2018)
Funding
Owned by M3 Inc (Japan)
Acquisitions
Acquired by M3 2018, acquired MSRA 2022
Expansion
Y - MSRA acquisition 2022, 23 locations across 8 states
Capacity & people
Investigators
—
Coordinators
—
CEO
Unknown
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
[email protected]
Tech & DCT
Builds tech
Unknown
Recruiting visible
Y
Notes
Founded 1984, acquired by M3 in Feb 2018. 21 fully owned/integrated sites across 7 states. 950K+ subject database. 6,300+ completed trials over 30+ years. Strong therapeutic expertise in GI, neuro, derm, endo, immunology. Strong Intera fit: large multi-site network, high enrollment track record, broad therapeutic mix, recruitment-focused. [Validated: 3 active recruiting cardiometabolic trials on ClinicalTrials.gov.]
Recommendation features (sample indication)
Ind fit 0.22Liftability 0.09Overall66
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.